Boston Scientific to Present Full Device Study at Meeting
This article is for subscribers only.
Boston Scientific Corp. said its study on a novel heart device to prevent strokes will be presented in full at a meeting March 9, after the company surprised investors and organizers earlier this week with plans to release only a limited look at the safety data.
Initial findings from the clinical trial, called Prevail, will be released at the American College of Cardiology meeting in San Francisco, the Natick, Massachusetts-based company said in a statement. The study tracked the safety of the Watchman device for a week after surgery and examined whether it reduced the risk of stroke, clots or death 18 months after treatment.